Business Context and Reporting Period
This Form 8-K Current Report was filed by eXegenics Inc. (not OPKO Health, Inc.) on May 3, 2007, with the earliest event reported on that date. The filing details significant executive leadership changes, including the departure of the President and the appointment of new officers, alongside the granting of stock options.
Key Financial Metrics and Agreements
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. However, it discloses specific compensation and severance figures:
- Severance for Departing President: Dr. Dale R. Pfost is to receive a severance payment equivalent to one year's salary ($325,000) paid in monthly installments, plus up to $65,000 in relocation expenses.
- New Executive Salaries:
- Dr. Phillip Frost (CEO): $325,000 annually
- Dr. Jane Hsiao (Vice Chairman/CTO): $300,000 annually
- Steven D. Rubin (EVP - Administration): $300,000 annually
- Dr. Rao Uppaluri (SVP/CFO): $275,000 annually
- Stock Options Granted: Options were granted with an exercise price of $4.88 per share (closing price on May 3, 2007).
- Phillip Frost: 1,000,000 options
- Jane Hsiao: 650,000 options
- Steven D. Rubin: 500,000 options
- Rao Uppaluri: 400,000 options
- Non-employee directors: 15,000 to 20,000 options each
Material Changes Versus Prior Period
The filing reports a material change in executive leadership:
- Departure: Dr. Dale R. Pfost, President, is departing the company effective May 31, 2007, following a settlement agreement.
- Appointments: On May 3, 2007, the company appointed Dr. Jane Hsiao as Vice Chairman and CTO, Steven D. Rubin as Executive Vice President of Administration, and Dr. Rao Uppaluri as Senior Vice President and CFO.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the operational impact of the executive turnover. The settlement agreement with the departing president includes a general release, and the new executive appointments were announced via a press release dated May 4, 2007.
Important Facts for Investor Verification
- Verify the exact vesting schedule for the 2.55 million options granted to executive officers (vesting in four equal annual installments).
- Confirm the total cash outflow impact of the $325,000 severance and $65,000 relocation package for the departing president.
- Review the full text of the Settlement Agreement (Exhibit 10.1) for any non-compete or non-solicitation clauses.
- Check subsequent filings to confirm the retention of the newly appointed CFO and CTO.